Stockscreener 앱 받기
4.83
0.82%
-0.04
시간 외 거래:
4.84
0.010
+0.21%
전일 마감가:
$4.87
열려 있는:
$4.85
하루 거래량:
241.44K
Relative Volume:
0.81
시가총액:
$128.17M
수익:
$59.07M
순이익/손실:
$-52.66M
주가수익비율:
-2.403
EPS:
-2.01
순현금흐름:
$-40.16M
1주 성능:
+0.00%
1개월 성능:
-19.37%
6개월 성능:
-39.47%
1년 성능:
-14.66%
1일 변동 폭
$4.83
$5.05
1주일 범위
$4.77
$5.24
52주 변동 폭
$4.3701
$11.30
Cvrx Inc Stock (CVRX) Company Profile
명칭
Cvrx Inc
전화
(763) 416-2850
주소
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
4.83 | 132.15M | 59.07M | -52.66M | -40.16M | -2.01 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-01-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-11 | 재확인 | Lake Street | Buy |
| 2024-05-01 | 재개 | Craig Hallum | Buy |
| 2024-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-05-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | 개시 | Lake Street | Buy |
| 2022-07-18 | 개시 | Craig Hallum | Buy |
| 2021-07-26 | 개시 | Canaccord Genuity | Buy |
| 2021-07-26 | 개시 | Piper Sandler | Overweight |
| 2021-07-26 | 개시 | William Blair | Outperform |
모두보기
Cvrx Inc 주식(CVRX)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
CVRX: CFO transition, expanded clinical trials, and improved reimbursement drive growth and adoption - TradingView
CVRX: CFO transition, strong Q1 growth, and expanded reimbursement drive U.S. market momentum - TradingView
CVRx CFO Jared Oasheim to step down after decade with company By Investing.com - Investing.com Australia
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating - Moomoo
CVRx CFO Jared Oasheim to step down - MSN
CVRx CFO Jared Oasheim to Resign, Will Stay Through Transition and Serve as Consultant - TradingView
Jared Oasheim to Resign as Chief Financial Officer of CVRx, Inc - marketscreener.com
[8-K] CVRx, Inc. Reports Material Event - Stock Titan
CVRx CFO Jared Oasheim to step down after decade with company - Investing.com
CVRx Announces Chief Financial Officer Transition - The Globe and Mail
CVRx Chief Financial Officer Jared Oasheim Leaving - Moomoo
Medical device firm CVRx plans CFO change, keeps him through Feb. 2027 - Stock Titan
CVRX News | CVRX INC (NASDAQ:CVRX) - ChartMill
CVRx stock up on Humana's Medicare coverage for Barostim therapy - MSN
CVRx, Inc. (CVRX) Presents at 46th Annual William Blair Growth Stock ConferenceSlideshow - Seeking Alpha
CVRx (NASDAQ: CVRX) director Nielsen awarded shares and 11,182-share option - Stock Titan
CVRx, Inc. (CVRX) director receives new share and option grants - Stock Titan
[Form 4] CVRx, Inc. Insider Trading Activity - Stock Titan
CVRx (CVRX) director granted 8,720 shares and options for 11,182 - Stock Titan
CVRx (CVRX) director receives new share and stock option awards - Stock Titan
Martha Shadan of CVRx, Inc. (CVRX) receives stock and option grants - Stock Titan
CVRx, Inc. (CVRX) director granted shares and stock options - Stock Titan
[Form 3] CVRx, Inc. Initial Statement of Beneficial Ownership - Stock Titan
William Blair Maintains CVRx Inc(CVRX.US) With Buy Rating - 富途牛牛
CVRx (CVRX) investors re-elect directors and ratify Grant Thornton as auditor - Stock Titan
CVRx, Inc. Elects Michael Dale as Director - marketscreener.com
Why (CVRX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
CVRX: Barostim drives heart failure innovation with strong clinical results and expanding market access - TradingView
CVRX: Barostim's clinical success and new Humana coverage drive expanded heart failure market access - TradingView
CVRx to present at Goldman Sachs Healthcare Con... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - marketscreener.com
CVRx Inc. (CVRX) Slips 1.04% as Stock Hovers Near Key Support ZoneMean Reversion Trade - thelegaladvocate.com
Understanding Momentum Shifts in (CVRX) - Stock Traders Daily
CVRx, Inc.Common Stock (NQ: CVRX - The Chronicle-Journal
CVRX Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Operational DisciplineFinal Results - The League of Women Voters of Texas
Clinical research teams accelerate progress in treatment options, CVRx asserts - Traders Union
CVRx to Present at the William Blair 46th Annual Growth Stock Conference - 富途牛牛
What Humana (HUM)'s Expanded Barostim Coverage Means For Shareholders - simplywall.st
CVRx to present at William Blair Growth Stock Conference on June 2, 2026 - Pluang
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill - Traders Union
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy - Yahoo Finance
CVRx rebounds as Humana issues Medicare policy for Barostim - MSN
CVRx Inc stock (US12674F1003): Medtronic takeover bid puts heart-device specialist in the spotlight - AD HOC NEWS
Number of shareholders of CVRx, Inc. – NASDAQ:CVRX - TradingView
CVRx Gains Momentum With Revenue Growth, BENEFIT-HF Progress and Humana Coverage Win - TipRanks
CVRx (CVRX) reports Q1 loss, beats revenue estimates - MSN
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Analysts Have Made A Financial Statement On CVRx, Inc.'s (NASDAQ:CVRX) First-Quarter Report - Yahoo Finance
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy - Sahm
Humana (HUM) Expands Medicare Advantage Coverage for Barostim Th - GuruFocus
Cvrx Inc (CVRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cvrx Inc 주식 (CVRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
2.43%
자본화:
|
볼륨(24시간):